Patients Discontinuing Anti-Obesity Medications Put On Weight at a Quadrupled Rate Compared to People Using Diet and Exercise

A recent study indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end traditional lifestyle regimens.

Published data in a leading health publication shows that while overweight people can lose a large proportion of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.

"Individuals buying such drugs must be informed of the risk of quick rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb.

Such speed of regain implies a return to starting mass in about 18 months.

Comparing Therapies

The research, which examined dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods.

Scientists point out that individuals who lose weight through lifestyle changes alone typically see a less rapid weight regain—around 0.1 kg a month—post-intervention.

Understanding the Fast Regain

Experts suggest the way of the drugs accounts for the accelerated regain.

GLP-1 drugs copy a natural hormone called GLP-1, which controls appetite.

"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.

"Stopping of this medication leads to appetite is uncontrolled, making binge eating a significant risk."

An Ongoing Issue?

Medical guidelines suggest the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.

A number of clinicians argue that, due to the high risk of relapse, the treatment is often long-term.

This opinion is reinforced by drug manufacturers, who state that the results "highlight the chronic character of obesity," similar to managing conditions like diabetes.

User Accounts

Users who have come off the medication explain a intense resurgence of appetite.

"I experienced something activating and you become starving," described an individual.

This challenge is compounded if individuals have not adopted sustainable dietary or behavioural modifications during therapy.

Growing Use

Figures suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.

• Adoption is more common among females than males.
• The 40s and 50s demographic shows the highest level of interest.
• A large proportion access the medications through private prescriptions rather than the NHS.

Finally, clinicians caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and long-term success hinges on combined lifestyle changes.